ATE388237T1 - Dendritische zellhybride - Google Patents

Dendritische zellhybride

Info

Publication number
ATE388237T1
ATE388237T1 AT98918140T AT98918140T ATE388237T1 AT E388237 T1 ATE388237 T1 AT E388237T1 AT 98918140 T AT98918140 T AT 98918140T AT 98918140 T AT98918140 T AT 98918140T AT E388237 T1 ATE388237 T1 AT E388237T1
Authority
AT
Austria
Prior art keywords
dendritic cell
cell hybrids
methods
dendritic
compositions
Prior art date
Application number
AT98918140T
Other languages
English (en)
Inventor
Jianlin Gong
Donald Kufe
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE388237T1 publication Critical patent/ATE388237T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464469—Tumor associated carbohydrates
    • A61K39/46447—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
AT98918140T 1997-04-15 1998-04-15 Dendritische zellhybride ATE388237T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4360997P 1997-04-15 1997-04-15

Publications (1)

Publication Number Publication Date
ATE388237T1 true ATE388237T1 (de) 2008-03-15

Family

ID=21928022

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98918140T ATE388237T1 (de) 1997-04-15 1998-04-15 Dendritische zellhybride

Country Status (8)

Country Link
US (1) US6652848B1 (de)
EP (1) EP1007720B1 (de)
JP (2) JP2002501377A (de)
AT (1) ATE388237T1 (de)
AU (1) AU744042B2 (de)
CA (1) CA2286873C (de)
DE (1) DE69839215T2 (de)
WO (1) WO1998046785A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273753B2 (en) * 1996-08-02 2007-09-25 Center Of Blood Research Purification and uses of dendritic cells and monocytes
US20050169898A1 (en) 1997-04-15 2005-08-04 Jianlin Gong Cell fusions and methods of making and using the same
AU2001238236B2 (en) * 1997-04-15 2007-02-15 Dana-Farber Cancer Institute, Inc. Cytotoxic t lymphocytes activated by dendritic cell hybrids
EP1071436A4 (de) * 1998-01-26 2003-08-27 Dana Farber Cancer Inst Inc Hybride immun-effektorzellen
US6389455B1 (en) * 1998-09-22 2002-05-14 Richard C. Fuisz Method and apparatus for bouncing electronic messages
CN1353575A (zh) * 1999-03-31 2002-06-12 匹兹堡大学联邦制高等教育 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞
EP1226235A2 (de) * 1999-10-22 2002-07-31 LESKOVAR, Peter Zellkonstrukte, die für die immuntherapie geeignet sind, deren herstellung und verwendung
KR100363587B1 (ko) * 1999-11-12 2002-12-06 이시우 대식세포와 종양세포의 융합에 의한 항종양 세포성 치료제
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
EP1248836B1 (de) * 2000-01-11 2005-06-15 Greenville Hospital System Herstellung von vakzinen unter der verwendung von hybrid-zellen
EP1541675A3 (de) * 2000-01-11 2007-08-08 Greenville Hospital System Aus Antigene presentierenden Zellen erhärtlich Zellhybride
US20070212338A1 (en) * 2000-01-11 2007-09-13 Greenville Hospital System Hybrid cells
US20090087450A1 (en) 2000-01-11 2009-04-02 Greenville Hospital System Combination therapy of hybrid cells with BCG injection for treating Cancer Patients
ATE374244T1 (de) * 2000-02-11 2007-10-15 Dana Farber Cancer Inst Inc Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
EP1130088A1 (de) * 2000-02-27 2001-09-05 Eberhard-Karls-Universität Tübingen Universitätsklinikum Hybridzellimfstoffe
DE10009030A1 (de) * 2000-02-27 2001-09-20 Univ Eberhard Karls Impfstoff
DE10024384A1 (de) * 2000-05-17 2001-11-29 Mack Gerd R Herstellung von dendritischen Zellen aus Rückenmarkstammzellen
EP1368061B1 (de) * 2000-10-20 2008-12-24 Tsuneya Ohno Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DE10139428A1 (de) * 2001-08-17 2003-03-27 Nemod Immuntherapie Ag Herstellung und Verwendung von humanen CD124 und CD116 positiven Tumorzelllinien zur Herstellung von allogenen oder semi-allogenen Immuntherapeutika
US20040115224A1 (en) * 2002-12-16 2004-06-17 Tsuneya Ohno Preparation and administration of hybrid cell vaccines for the prevention of cancer
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050180951A1 (en) * 2004-02-12 2005-08-18 Tsuneya Ohno Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer
JPWO2005083062A1 (ja) * 2004-02-26 2008-01-17 ジェノミディア株式会社 細胞ワクチン
AU2005218638A1 (en) * 2004-03-02 2005-09-15 Donald W. Kufe Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
EP2630968A1 (de) 2006-06-30 2013-08-28 Baylor Research Institute Mithilfe von GM-CSF und Interfron alpha erzeugte und mit hitzebehandelten und getöteten Krebszellen geladene dendritische Zellen
CN109385400A (zh) * 2017-08-09 2019-02-26 科济生物医药（上海）有限公司 共表达pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
WO2022216942A1 (en) 2021-04-07 2022-10-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348878A (en) 1990-05-10 1994-09-20 Dana-Farber Cancer Institute Class I MHC-restricted T-T hybridomas, and a CD8-transfected BW5147, fusion partner therefor
AU687733B2 (en) 1992-04-01 1998-03-05 Rockefeller University, The Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
DK0633929T3 (da) 1992-04-01 2004-06-28 Univ Rockefeller Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
IT1264516B1 (it) 1993-05-31 1996-09-24 Biotop Sas Di Rita Cassarin Cellule dendritiche immortalizzate
KR100326132B1 (ko) * 1993-10-01 2002-07-31 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 호흡기마스크및이호흡기마스크에사용되는음성전달어댑터
WO1995016775A1 (en) 1993-12-14 1995-06-22 Yajun Guo Tumor cell fusions and methods for use of such tumor cell fusions
AU3586595A (en) 1994-09-09 1996-03-27 Zymogenetics Inc. Preparation of immortalized cells
EP0839044B1 (de) 1995-03-31 2005-05-18 Universite Libre De Bruxelles DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT
WO1998017300A1 (en) * 1996-10-25 1998-04-30 Dana-Farber Cancer Institute, Inc. Mucin-mediated immunomodulation
CN1353575A (zh) 1999-03-31 2002-06-12 匹兹堡大学联邦制高等教育 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t－销细胞

Also Published As

Publication number Publication date
EP1007720B1 (de) 2008-03-05
JP2002501377A (ja) 2002-01-15
DE69839215T2 (de) 2009-03-19
CA2286873A1 (en) 1998-10-22
DE69839215D1 (de) 2008-04-17
CA2286873C (en) 2010-07-13
JP2008263997A (ja) 2008-11-06
EP1007720A1 (de) 2000-06-14
US6652848B1 (en) 2003-11-25
AU7112098A (en) 1998-11-11
AU744042B2 (en) 2002-02-14
WO1998046785A1 (en) 1998-10-22
EP1007720A4 (de) 2001-10-24

Similar Documents

Publication Publication Date Title
DE69839215D1 (de) Dendritische zellhybride
AP2001002225A0 (en) 1-heterocycle substituted diarylamines.
BRPI0410321A (pt) célula eletroquìmica, método de geração de uma corrente elétrica, e, gerador eletroquìmico de hidrogênio
ATE234323T1 (de) N6-heterocyclisch substituierte adenosin-derivate
EP1357403A3 (de) Verfahren zur Erzeugung elektrischer Energie in einem Bohrloch
NO912473D0 (no) Tynn, roerformet, selvbaerende elektrode for elektrokjemiske celler.
AU2002364935A1 (en) Enhancement of immune responses by 4-1bb-binding agents
BG103251A (en) Oxydiazols, methods for their preparation and application as medicamentous forms
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
MX9800125A (es) Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
DK0842289T3 (da) Homolog rekombination i eukaryote celler med inaktiveret fejlparringsreparation
NZ305799A (en) Cyclic amidino agents useful as nitric oxide synthase inhibitors
AU6505299A (en) Methods for generating antigen-reactive t cells (in vitro)
DK1025245T3 (da) Hurtig etablering af stabile pattedyrscelelinjer, der producerer höje koncentrationer af rekombinante proteiner
AU4791901A (en) Compositions and methods for dendritic cell-based immunotherapy
ES8305039A1 (es) "metodo de producir nuevas lineas de celulas t humanas".
MX9802730A (es) Agonistas receptores hematopoyeticos multifuncionales.
MX9602557A (es) Proteinas de higado de mamifero y su uso en oncologia.
BG104291A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
TW324824B (en) Monocrystalline synchronous DRAM system
CA2218129A1 (en) Chimeric mcp and daf proteins with cell surface localizing domain
ZA9810371B (en) Th2 cell depletion; compositions; methods.
IL139604A0 (en) Novel peptides
IL142596A0 (en) Baculovirus expression system
BG102287A (en) New anticonvulsion 1-ar(alk)-imidazolin-2-ons with diasubstituted amine residue in forth place and method for their preparation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties